Skip to main content

Advertisement

SpringerLink
Log in

Neurofibromatosis type1, type 2, tuberous sclerosis and Von Hippel-Lindau disease

  • Review
  • Published:
Child's Nervous System Aims and scope Submit manuscript

Abstract

Neurocutaneous syndromes (also known as phakomatoses) are heterogenous group of disorders that involve derivatives of the neuroectoderm. Each disease has diagnostic and pathognomonic criteria, once identified, thorough clinical examination to the patient and the family members should be done. Magnetic resonance imaging (MRI) is used to study the pathognomonic findings withing the CNS (Evans et al. in Am J Med Genet A 152A:327–332, 2010). This chapter includes the 4 most common syndromes faced by neurosurgeons and neurologists; neurofibromatosis types 1 and 2, tuberous sclerosis and Von Hippel-Lindau disease. Each syndrome has specific genetic anomaly that involves a tumor suppressor gene and the loss of inhibition of specific pathways. The result is a spectrum of cutaneous manifestations and neoplasms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, Lalloo F (2010) Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 152A:327–332

    Article  CAS  PubMed  Google Scholar 

  2. Rasmussen SA, Yang Q, Friedman JM (2001) Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet 68:1110–1118

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Cawthon RM, Weiss R, Xu GF, Viskochil D, Culver M, Stevens J, Robertson M, Dunn D, Gesteland R, O’Connell P et al (1990) A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 62:193–201

    Article  CAS  PubMed  Google Scholar 

  4. DeClue JE, Papageorge AG, Fletcher JA, Diehl SR, Ratner N, Vass WC, Lowy DR (1992) Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 69:265–273

    Article  CAS  PubMed  Google Scholar 

  5. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954

    Article  CAS  PubMed  Google Scholar 

  6. Pfister S, Janzarik WG, Remke M, Ernst A, Werft W, Becker N, Toedt G, Wittmann A, Kratz C, Olbrich H, Ahmadi R, Thieme B, Joos S, Radlwimmer B, Kulozik A, Pietsch T, Herold-Mende C, Gnekow A, Reifenberger G, Korshunov A, Scheurlen W, Omran H, Lichter P (2008) BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 118:1739–1749

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Kaul A, Chen YH, Emnett RJ, Dahiya S, Gutmann DH (2012) Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner. Genes dev 26:2561–2566

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Gutmann DH (2008) Using neurofibromatosis-1 to better understand and treat pediatric low-grade glioma. J Child Neurol 23:1186–1194

    Article  PubMed  PubMed Central  Google Scholar 

  9. DA S (1988) Neurofibromatosis. Conference statement. National institutes of health consensus development conference. Arch Neurol 45:575–578

  10. Carey JC, Laub JM, Hall BD (1979) Penetrance and variability in neurofibromatosis: a genetic study of 60 families. Birth Defects Orig Artic Ser 15:271–281

    CAS  PubMed  Google Scholar 

  11. North K (1993) Neurofibromatosis type 1: review of the first 200 patients in an Australian clinic. J Child Neurol 8:395–402

    Article  CAS  PubMed  Google Scholar 

  12. Cohen BH, Rothner AD (1989) Incidence, types, and management of cancer in patients with neurofibromatosis. Oncology (Williston Park) 3:23–30; discussion 34, 37–28

  13. Crawford AH, Schorry EK (2006) Neurofibromatosis update. J Pediatr Orthop 26:413–423

    Article  PubMed  Google Scholar 

  14. Messiaen LM, Callens T, Mortier G, Beysen D, Vandenbroucke I, Van Roy N, Speleman F, Paepe AD (2000) Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat 15:541–555

    Article  CAS  PubMed  Google Scholar 

  15. Koczkowska M, Callens T, Gomes A, Sharp A, Chen Y, Hicks AD, Aylsworth AS, Azizi AA, Basel DG, Bellus G, Bird LM, Blazo MA, Burke LW, Cannon A, Collins F, DeFilippo C, Denayer E, Digilio MC, Dills SK, Dosa L, Greenwood RS, Griffis C, Gupta P, Hachen RK, Hernandez-Chico C, Janssens S, Jones KJ, Jordan JT, Kannu P, Korf BR, Lewis AM, Listernick RH, Lonardo F, Mahoney MJ, Ojeda MM, McDonald MT, McDougall C, Mendelsohn N, Miller DT, Mori M, Oostenbrink R, Perreault S, Pierpont ME, Piscopo C, Pond DA, Randolph LM, Rauen KA, Rednam S, Rutledge SL, Saletti V, Schaefer GB, Schorry EK, Scott DA, Shugar A, Siqveland E, Starr LJ, Syed A, Trapane PL, Ullrich NJ, Wakefield EG, Walsh LE, Wangler MF, Zackai E, Claes KBM, Wimmer K, van Minkelen R, De Luca A, Martin Y, Legius E, Messiaen LM (2019) Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype-phenotype correlation. Genet Med 21:867–876

    Article  CAS  PubMed  Google Scholar 

  16. Lee W, Teckie S, Wiesner T, Ran L, Prieto Granada CN, Lin M, Zhu S, Cao Z, Liang Y, Sboner A, Tap WD, Fletcher JA, Huberman KH, Qin LX, Viale A, Singer S, Zheng D, Berger MF, Chen Y, Antonescu CR, Chi P (2014) PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet 46:1227–1232

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Duffner PK, Cohen ME, Seidel FG, Shucard DW (1989) The significance of MRI abnormalities in children with neurofibromatosis. Neurology 39:373–378

    Article  CAS  PubMed  Google Scholar 

  18. North K, Joy P, Yuille D, Cocks N, Mobbs E, Hutchins P, McHugh K, de Silva M (1994) Specific learning disability in children with neurofibromatosis type 1: significance of MRI abnormalities. Neurology 44:878–883

    Article  CAS  PubMed  Google Scholar 

  19. Brems H, Chmara M, Sahbatou M, Denayer E, Taniguchi K, Kato R, Somers R, Messiaen L, De Schepper S, Fryns JP, Cools J, Marynen P, Thomas G, Yoshimura A, Legius E (2007) Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet 39:1120–1126

    Article  CAS  PubMed  Google Scholar 

  20. Wimmer K, Etzler J (2008) Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg? Hum Genet 124:105–122

    Article  PubMed  Google Scholar 

  21. Ejarque I, Millan-Salvador JM, Oltra S, Pesudo-Martinez JV, Beneyto M, Perez-Aytes A (2015) Arnold-Chiari malformation in Noonan syndrome and other syndromes of the RAS/MAPK pathway. Rev Neurol 60:408–412

    PubMed  Google Scholar 

  22. Huson SM, Harper PS, Compston DA (1988) Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain 111 ( Pt 6):1355–1381

  23. Fisher ER, Vuzevski VD (1968) Cytogenesis of schwannoma (neurilemoma), neurofibroma, dermatofibroma, and dermatofibrosarcoma as revealed by electron microscopy. Am J Clin Pathol 49:141–154

    Article  CAS  PubMed  Google Scholar 

  24. Friedrich RE, Korf B, Funsterer C, Mautner VF (2003) Growth type of plexiform neurofibromas in NF1 determined on magnetic resonance images. Anticancer Res 23:949–952

    CAS  PubMed  Google Scholar 

  25. Tonsgard JH, Kwak SM, Short MP, Dachman AH (1998) CT imaging in adults with neurofibromatosis-1: frequent asymptomatic plexiform lesions. Neurology 50:1755–1760

    Article  CAS  PubMed  Google Scholar 

  26. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM (1986) Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 57:2006–2021

    Article  CAS  PubMed  Google Scholar 

  27. Sordillo PP, Helson L, Hajdu SI, Magill GB, Kosloff C, Golbey RB, Beattie EJ (1981) Malignant schwannoma–clinical characteristics, survival, and response to therapy. Cancer 47:2503–2509

    Article  CAS  PubMed  Google Scholar 

  28. James H. Tonsgard BYaDMF (2012) Surgical management of neurofibromatosis types 1 and 2. In: Quinones-Hinojosa A (ed) Schmidek and sweet operative neurosurgical techniques, 6th edn. Elsevier Saunders, Philadelphia, PA, pp 579–587

  29. Hammond JA, Driedger AA (1978) Detection of malignant change in neurofibromatosis (von Recklinghausen’s disease) by gallium-67 scanning. Can Med Assoc J 119:352–353

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Kloos RT, Rufini V, Gross MD, Shapiro B (1996) Bone scans in neurofibromatosis: neurofibroma, plexiform neuroma and neurofibrosarcoma. J Nucl Med 37:1778–1783

    CAS  PubMed  Google Scholar 

  31. Donaldson EK, Winter JM, Chandler RM, Clark TA, Giuffre JL (2023) Malignant peripheral nerve sheath tumors of the brachial plexus: a single-center experience on diagnosis, management, and outcomes. Ann Plast Surg 90:339–342

    Article  CAS  PubMed  Google Scholar 

  32. Erkulvrawatr S, El Gammal T, Hawkins J, Green JB, Srinivasan G (1979) Intrathoracic meningoceles and neurofibromatosis Arch neurol 36:557–559

    Article  CAS  PubMed  Google Scholar 

  33. Cho DG, Chang YJ, Cho KD, Hong JT (2015) Collaborative treatment of huge intrathoracic meningoceles associated with neurofibromatosis type 1: a case report. J Cardiothorac Surg 10:161

    Article  PubMed  PubMed Central  Google Scholar 

  34. Heidary G, Fisher MJ, Liu GT, Ferner RE, Gutmann DH, Listernick RH, Kapur K, Loguidice M, Ardern-Holmes SL, Avery RA, Hammond C, Hoffman RO, Hummel TR, Kuo A, Reginald A, Ullrich NJ (2020) Visual field outcomes in children treated for neurofibromatosis type 1-associated optic pathway gliomas: a multicenter retrospective study. J AAPOS 24:349 e341–349 e345

  35. Listernick R, Louis DN, Packer RJ, Gutmann DH (1997) Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 optic pathway glioma task force. Ann Neurol 41:143–149

    Article  CAS  PubMed  Google Scholar 

  36. Kleihues P, Soylemezoglu F, Schauble B, Scheithauer BW, Burger PC (1995) Histopathology, classification, and grading of gliomas. Glia 15:211–221

    Article  CAS  PubMed  Google Scholar 

  37. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO Classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231–1251

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Packer RJ, Ater J, Allen J, Phillips P, Geyer R, Nicholson HS, Jakacki R, Kurczynski E, Needle M, Finlay J, Reaman G, Boyett JM (1997) Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 86:747–754

    Article  CAS  PubMed  Google Scholar 

  39. Sorensen SA, Mulvihill JJ, Nielsen A (1986) Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms. N Engl J Med 314:1010–1015

    Article  CAS  PubMed  Google Scholar 

  40. Molloy PT, Bilaniuk LT, Vaughan SN, Needle MN, Liu GT, Zackai EH, Phillips PC (1995) Brainstem tumors in patients with neurofibromatosis type 1: a distinct clinical entity. Neurology 45:1897–1902

    Article  CAS  PubMed  Google Scholar 

  41. Pollack IF, Shultz B, Mulvihill JJ (1996) The management of brainstem gliomas in patients with neurofibromatosis 1. Neurology 46:1652–1660

    Article  CAS  PubMed  Google Scholar 

  42. Horwich A, Riccardi VM, Francke U (1983) Brief clinical report: aqueductal stenosis leading to hydrocephalus–an unusual manifestation of neurofibromatosis. Am J Med Genet 14:577–581

    Article  CAS  PubMed  Google Scholar 

  43. Dincer A, Yener U, Ozek MM (2011) Hydrocephalus in patients with neurofibromatosis type 1: MR imaging findings and the outcome of endoscopic third ventriculostomy. AJNR Am J Neuroradiol 32:643–646

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Landry JP, Schertz KL, Chiang YJ, Bhalla AD, Yi M, Keung EZ, Scally CP, Feig BW, Hunt KK, Roland CL, Guadagnolo A, Bishop AJ, Lazar AJ, Slopis JM, McCutcheon IE, Torres KE (2021) Comparison of cancer prevalence in patients with neurofibromatosis type 1 at an academic cancer center vs in the general population from 1985 to 2020. JAMA Netw Open 4:e210945

    Article  PubMed  PubMed Central  Google Scholar 

  45. Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, Packer RJ, Tabori U, Hoffman RO, Ardern-Holmes SL, Hummel TR, Hargrave DR, Bouffet E, Charrow J, Bilaniuk LT, Balcer LJ, Liu GT (2012) Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol 14:790–797

    Article  PubMed  PubMed Central  Google Scholar 

  46. Lafay-Cousin L, Sung L, Carret AS, Hukin J, Wilson B, Johnston DL, Zelcer S, Silva M, Odame I, Mpofu C, Strother D, Bouffet E (2008) Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: a Canadian pediatric brain tumor consortium experience. Cancer 112:892–899

    Article  CAS  PubMed  Google Scholar 

  47. Maris JM, Wiersma SR, Mahgoub N, Thompson P, Geyer RJ, Hurwitz CG, Lange BJ, Shannon KM (1997) Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1. Cancer 79:1438–1446

    Article  CAS  PubMed  Google Scholar 

  48. de Blank P, Li N, Fisher MJ, Ullrich NJ, Bhatia S, Yasui Y, Sklar CA, Leisenring W, Howell R, Oeffinger K, Hardy K, Okcu MF, Gibson TM, Robison LL, Armstrong GT, Krull KR (2020) Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer survivor study. Genet Med 22:1794–1802

    Article  PubMed  PubMed Central  Google Scholar 

  49. Shannon KM, O’Connell P, Martin GA, Paderanga D, Olson K, Dinndorf P, McCormick F (1994) Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 330:597–601

    Article  CAS  PubMed  Google Scholar 

  50. Cardellicchio S, Bacci G, Farina S, Genitori L, Massimino M, de Martino M, Caputo R, Sardi I (2014) Low-dose cisplatin-etoposide regimen for patients with optic pathway glioma: a report of four cases and literature review. Neuropediatrics 45:42–49

    Article  PubMed  Google Scholar 

  51. Gururangan S, Fisher MJ, Allen JC, Herndon JE 2nd, Quinn JA, Reardon DA, Vredenburgh JJ, Desjardins A, Phillips PC, Watral MA, Krauser JM, Friedman AH, Friedman HS (2007) Temozolomide in children with progressive low-grade glioma. Neuro Oncol 9:161–168

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Lassaletta A, Scheinemann K, Zelcer SM, Hukin J, Wilson BA, Jabado N, Carret AS, Lafay-Cousin L, Larouche V, Hawkins CE, Pond GR, Poskitt K, Keene D, Johnston DL, Eisenstat DD, Krishnatry R, Mistry M, Arnoldo A, Ramaswamy V, Huang A, Bartels U, Tabori U, Bouffet E (2016) Phase II weekly vinblastine for chemotherapy-naive children with progressive low-grade glioma: a Canadian pediatric brain tumor consortium study. J Clin Oncol 34:3537–3543

    Article  CAS  PubMed  Google Scholar 

  53. Cappellano AM, Petrilli AS, da Silva NS, Silva FA, Paiva PM, Cavalheiro S, Bouffet E (2015) Single agent vinorelbine in pediatric patients with progressive optic pathway glioma. J Neurooncol 121:405–412

    Article  CAS  PubMed  Google Scholar 

  54. Falzon K, Drimtzias E, Picton S, Simmons I (2018) Visual outcomes after chemotherapy for optic pathway glioma in children with and without neurofibromatosis type 1: results of the International Society of Paediatric Oncology (SIOP) Low-grade glioma 2004 trial UK cohort. Br J Ophthalmol 102:1367–1371

    Article  PubMed  Google Scholar 

  55. Banerjee A, Jakacki RI, Onar-Thomas A, Wu S, Nicolaides T, Young Poussaint T, Fangusaro J, Phillips J, Perry A, Turner D, Prados M, Packer RJ, Qaddoumi I, Gururangan S, Pollack IF, Goldman S, Doyle LA, Stewart CF, Boyett JM, Kun LE, Fouladi M (2017) A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro Oncol 19:1135–1144

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. LoRusso PM, Krishnamurthi SS, Rinehart JJ, Nabell LM, Malburg L, Chapman PB, DePrimo SE, Bentivegna S, Wilner KD, Tan W, Ricart AD (2010) Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 16:1924–1937

    Article  CAS  PubMed  Google Scholar 

  57. McCannel TA, Chmielowski B, Finn RS, Goldman J, Ribas A, Wainberg ZA, McCannel CA (2014) Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer. JAMA Ophthalmol 132:1005–1009

    Article  PubMed  Google Scholar 

  58. Mendez-Martinez S, Calvo P, Ruiz-Moreno O, Pardinas Baron N, Lecinena Bueno J, Gil Ruiz MDR, Pablo L (2019) Ocular adverse events associated with Mek inhibitors. Retina 39:1435–1450

    Article  CAS  PubMed  Google Scholar 

  59. Nolan DP, Lewis S, Hariprasad SM (2016) Retinal toxicity associated with MEK inhibitor use for metastatic cancer: a rising trend in ophthalmology. OPhthalmic Surg Lasers Imaging Retina 47:398–402

    Article  PubMed  Google Scholar 

  60. Bartels U, Hawkins C, Jing M, Ho M, Dirks P, Rutka J, Stephens D, Bouffet E (2006) Vascularity and angiogenesis as predictors of growth in optic pathway/hypothalamic gliomas. J Neurosurg 104:314–320

    PubMed  Google Scholar 

  61. Machein MR, Plate KH (2000) VEGF in brain tumors. J Neurooncol 50:109–120

    Article  CAS  PubMed  Google Scholar 

  62. Presta LG, Chen H, O’Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593–4599

    CAS  PubMed  Google Scholar 

  63. Hwang EI, Jakacki RI, Fisher MJ, Kilburn LB, Horn M, Vezina G, Rood BR, Packer RJ (2013) Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatr Blood Cancer 60:776–782

    Article  CAS  PubMed  Google Scholar 

  64. Gururangan S, Fangusaro J, Poussaint TY, McLendon RE, Onar-Thomas A, Wu S, Packer RJ, Banerjee A, Gilbertson RJ, Fahey F, Vajapeyam S, Jakacki R, Gajjar A, Goldman S, Pollack IF, Friedman HS, Boyett JM, Fouladi M, Kun LE (2014) Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas–a pediatric brain tumor consortium study. Neuro Oncol 16:310–317

    Article  CAS  PubMed  Google Scholar 

  65. Kalra M, Heath JA, Kellie SJ, Dalla Pozza L, Stevens MM, Swamy S, McCowage GB (2015) Confirmation of bevacizumab activity, and maintenance of efficacy in retreatment after subsequent relapse, in pediatric low-grade glioma. J Pediatr Hematol Oncol 37:e341-346

    Article  CAS  PubMed  Google Scholar 

  66. Grabenbauer GG, Schuchardt U, Buchfelder M, Rodel CM, Gusek G, Marx M, Doerr HG, Fahlbusch R, Huk WJ, Wenzel D, Sauer R (2000) Radiation therapy of optico-hypothalamic gliomas (OHG)–radiographic response, vision and late toxicity. Radiother Oncol 54:239–245

    Article  CAS  PubMed  Google Scholar 

  67. Lacaze E, Kieffer V, Streri A, Lorenzi C, Gentaz E, Habrand JL, Dellatolas G, Kalifa C, Grill J (2003) Neuropsychological outcome in children with optic pathway tumours when first-line treatment is chemotherapy. Br J Cancer 89:2038–2044

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Stieber VW (2008) Radiation therapy for visual pathway tumors. J Neuroophthalmol 28:222–230

    Article  PubMed  Google Scholar 

  69. Combs SE, Schulz-Ertner D, Moschos D, Thilmann C, Huber PE, Debus J (2005) Fractionated stereotactic radiotherapy of optic pathway gliomas: tolerance and long-term outcome. Int J Radiat Oncol Biol Phys 62:814–819

    Article  PubMed  Google Scholar 

  70. Saran FH, Baumert BG, Khoo VS, Adams EJ, Garre ML, Warrington AP, Brada M (2002) Stereotactically guided conformal radiotherapy for progressive low-grade gliomas of childhood. Int J Radiat Oncol Biol Phys 53:43–51

    Article  PubMed  Google Scholar 

  71. Hug EB, Muenter MW, Archambeau JO, DeVries A, Liwnicz B, Loredo LN, Grove RI, Slater JD (2002) Conformal proton radiation therapy for pediatric low-grade astrocytomas. Strahlenther Onkol 178:10–17

    Article  PubMed  Google Scholar 

  72. Liang CL, Lu K, Liliang PC, Chen HJ (2010) Gamma knife surgery for optic glioma. Report of 2 cases. J Neurosurg 113 Suppl:44–47

  73. Evans DG, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R (2005) Incidence of vestibular schwannoma and neurofibromatosis 2 in the north west of England over a 10-year period: higher incidence than previously thought. Otol Neurotol 26:93–97

    Article  PubMed  Google Scholar 

  74. Antinheimo J, Sankila R, Carpen O, Pukkala E, Sainio M, Jaaskelainen J (2000) Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology 54:71–76

    Article  CAS  PubMed  Google Scholar 

  75. Rong R, Tang X, Gutmann DH, Ye K (2004) Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. Proc Natl Acad Sci USA 101:18200–18205

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Plotkin SR, Messiaen L, Legius E, Pancza P, Avery RA, Blakeley JO, Babovic-Vuksanovic D, Ferner R, Fisher MJ, Friedman JM, Giovannini M, Gutmann DH, Hanemann CO, Kalamarides M, Kehrer-Sawatzki H, Korf BR, Mautner VF, MacCollin M, Papi L, Rauen KA, Riccardi V, Schorry E, Smith MJ, Stemmer-Rachamimov A, Stevenson DA, Ullrich NJ, Viskochil D, Wimmer K, Yohay K, International consensus group on neurofibromatosis diagnostic C, Huson SM, Wolkenstein P, Evans DG (2022) Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation. Genet Med 24:1967–1977

    Article  Google Scholar 

  77. Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N (1994) Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 52:450–461

    Article  CAS  PubMed  Google Scholar 

  78. Evans DG, Wallace AJ, Wu CL, Trueman L, Ramsden RT, Strachan T (1998) Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis. Am J Hum Genet 63:727–736

    CAS  PubMed  PubMed Central  Google Scholar 

  79. Plotkin SR, Blakeley JO, Evans DG, Hanemann CO, Hulsebos TJ, Hunter-Schaedle K, Kalpana GV, Korf B, Messiaen L, Papi L, Ratner N, Sherman LS, Smith MJ, Stemmer-Rachamimov AO, Vitte J, Giovannini M (2013) Update from the 2011 International Schwannomatosis Workshop: from genetics to diagnostic criteria. Am J Med Genet A 161A:405–416

    Article  PubMed  Google Scholar 

  80. Pulst SM, Rouleau GA, Marineau C, Fain P, Sieb JP (1993) Familial meningioma is not allelic to neurofibromatosis 2. Neurology 43:2096–2098

    Article  CAS  PubMed  Google Scholar 

  81. Evans DGR, Salvador H, Chang VY, Erez A, Voss SD, Druker H, Scott HS, Tabori U (2017) Cancer and central nervous system tumor surveillance in pediatric neurofibromatosis 2 and related disorders. Clin Cancer Res 23:e54–e61

    Article  CAS  PubMed  Google Scholar 

  82. Evans DG (2009) Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis 4:16

    Article  PubMed  PubMed Central  Google Scholar 

  83. Evans DG (2009) Neurofibromatosis 2 [bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]. Genet Med 11:599–610

    Article  PubMed  Google Scholar 

  84. Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, Harris R (1992) A clinical study of type 2 neurofibromatosis. Q J Med 84:603–618

    CAS  PubMed  Google Scholar 

  85. Evans DG, Baser ME, O’Reilly B, Rowe J, Gleeson M, Saeed S, King A, Huson SM, Kerr R, Thomas N, Irving R, MacFarlane R, Ferner R, McLeod R, Moffat D, Ramsden R (2005) Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg 19:5–12

    Article  CAS  PubMed  Google Scholar 

  86. Sobel RA (1993) Vestibular (acoustic) schwannomas: histologic features in neurofibromatosis 2 and in unilateral cases. J Neuropathol Exp Neurol 52:106–113

    Article  CAS  PubMed  Google Scholar 

  87. Hamada Y, Iwaki T, Fukui M, Tateishi J (1997) A comparative study of embedded nerve tissue in six NF2-associated schwannomas and 17 nonassociated NF2 schwannomas. Surg Neurol 48:395–400

    Article  CAS  PubMed  Google Scholar 

  88. Nowak A, Dziedzic T, Czernicki T, Kunert P, Marchel A (2016) Management of spinal tumors in neurofibromatosis type 2 patients. Neurol Neurochir Pol 50:31–35

    Article  PubMed  Google Scholar 

  89. Louis DN, Ramesh V, Gusella JF (1995) Neuropathology and molecular genetics of neurofibromatosis 2 and related tumors. Brain pathol 5:163–172

    Article  CAS  PubMed  Google Scholar 

  90. McCormick PC, Torres R, Post KD, Stein BM (1990) Intramedullary ependymoma of the spinal cord. J Neurosurg 72:523–532

    Article  CAS  PubMed  Google Scholar 

  91. Rubinstein LJ (1986) The malformative central nervous system lesions in the central and peripheral forms of neurofibromatosis. A neuropathological study of 22 cases. Ann N Y Acad Sci 486:14–29

    Article  CAS  PubMed  Google Scholar 

  92. Matsushima K, Kohno M, Nakajima N (2019) Hearing preservation in vestibular schwannoma surgery via retrosigmoid transmeatal approach. Acta Neurochir (Wien) 161:2265–2269

    Article  PubMed  Google Scholar 

  93. Mathieu D, Kondziolka D, Flickinger JC, Niranjan A, Williamson R, Martin JJ, Lunsford LD (2007) Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates. Neurosurgery 60:460–468; discussion 468–470

  94. Yanni DS, Ulkatan S, Deletis V, Barrenechea IJ, Sen C, Perin NI (2010) Utility of neurophysiological monitoring using dorsal column mapping in intramedullary spinal cord surgery. J Neurosurg Spine 12:623–628

    Article  PubMed  Google Scholar 

  95. Morris KA, Golding JF, Axon PR, Afridi S, Blesing C, Ferner RE, Halliday D, Jena R, Pretorius PM, group UNR, Evans DG, McCabe MG, Parry A (2016) Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation. Neurooncol Pract 3:281–289

    PubMed  PubMed Central  Google Scholar 

  96. Mautner VF, Nguyen R, Kutta H, Fuensterer C, Bokemeyer C, Hagel C, Friedrich RE, Panse J (2010) Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol 12:14–18

    Article  PubMed  Google Scholar 

  97. Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361:358–367

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Snyder MH, Ampie L, DiDomenico JD, Asthagiri AR (2021) Bevacizumab as a surgery-sparing agent for spinal ependymoma in patients with neurofibromatosis type II: systematic review and case. J Clin Neurosci 86:79–84

    Article  CAS  PubMed  Google Scholar 

  99. Goutagny S, Raymond E, Esposito-Farese M, Trunet S, Mawrin C, Bernardeschi D, Larroque B, Sterkers O, Giovannini M, Kalamarides M (2015) Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. J Neurooncol 122:313–320

    Article  CAS  PubMed  Google Scholar 

  100. Northrup H, Krueger DA, International Tuberous Sclerosis Complex Consensus G (2013) tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 49:243–254

    Article  Google Scholar 

  101. Roach ES (2016) Applying the Lessons of Tuberous Sclerosis: The 2015 Hower Award Lecture. Pediatr Neurol 63:6–22

    Article  PubMed  Google Scholar 

  102. Jones AC, Shyamsundar MM, Thomas MW, Maynard J, Idziaszczyk S, Tomkins S, Sampson JR, Cheadle JP (1999) Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet 64:1305–1315

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Au KS, Williams AT, Roach ES, Batchelor L, Sparagana SP, Delgado MR, Wheless JW, Baumgartner JE, Roa BB, Wilson CM, Smith-Knuppel TK, Cheung MY, Whittemore VH, King TM, Northrup H (2007) Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet Med 9:88–100

    Article  CAS  PubMed  Google Scholar 

  104. Crino PB, Nathanson KL, Henske EP (2006) The tuberous sclerosis complex. N Engl J Med 355:1345–1356

    Article  CAS  PubMed  Google Scholar 

  105. Schwartz RA, Fernandez G, Kotulska K, Jozwiak S (2007) Tuberous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol 57:189–202

    Article  PubMed  Google Scholar 

  106. Curatolo P, Bombardieri R, Jozwiak S (2008) Tuberous sclerosis. Lancet 372:657–668

    Article  CAS  PubMed  Google Scholar 

  107. van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S, Lindhout D, van den Ouweland A, Halley D, Young J, Burley M, Jeremiah S, Woodward K, Nahmias J, Fox M, Ekong R, Osborne J, Wolfe J, Povey S, Snell RG, Cheadle JP, Jones AC, Tachataki M, Ravine D, Sampson JR, Reeve MP, Richardson P, Wilmer F, Munro C, Hawkins TL, Sepp T, Ali JB, Ward S, Green AJ, Yates JR, Kwiatkowska J, Henske EP, Short MP, Haines JH, Jozwiak S, Kwiatkowski DJ (1997) Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 277:805–808

    Article  PubMed  Google Scholar 

  108. Caban C, Khan N, Hasbani DM, Crino PB (2017) Genetics of tuberous sclerosis complex: implications for clinical practice. Appl Clin Genet 10:1–8

    Article  CAS  PubMed  Google Scholar 

  109. Northrup H, Aronow ME, Bebin EM, Bissler J, Darling TN, de Vries PJ, Frost MD, Fuchs Z, Gosnell ES, Gupta N, Jansen AC, Jozwiak S, Kingswood JC, Knilans TK, McCormack FX, Pounders A, Roberds SL, Rodriguez-Buritica DF, Roth J, Sampson JR, Sparagana S, Thiele EA, Weiner HL, Wheless JW, Towbin AJ, Krueger DA, International Tuberous Sclerosis Complex Consensus G (2021) Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatr Neurol 123:50–66

    Article  Google Scholar 

  110. Verhoef S, Bakker L, Tempelaars AM, Hesseling-Janssen AL, Mazurczak T, Jozwiak S, Fois A, Bartalini G, Zonnenberg BA, van Essen AJ, Lindhout D, Halley DJ, van den Ouweland AM (1999) High rate of mosaicism in tuberous sclerosis complex. Am J Hum Genet 64:1632–1637

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Krueger DA, Northrup H, International Tuberous Sclerosis Complex Consensus G (2013) Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 49:255–265

    Article  Google Scholar 

  112. Farach LS, Pearson DA, Woodhouse JP, Schraw JM, Sahin M, Krueger DA, Wu JY, Bebin EM, Lupo PJ, Au KS, Northrup H, Group TS (2019) Tuberous sclerosis complex genotypes and developmental phenotype. Pediatr Neurol 96:58–63

    Article  Google Scholar 

  113. Yates JR, Maclean C, Higgins JN, Humphrey A, le Marechal K, Clifford M, Carcani-Rathwell I, Sampson JR, Bolton PF, Tuberous Sclerosis Study G (2011) The tuberous sclerosis 2000 study: presentation, initial assessments and implications for diagnosis and management. Arch Dis Child 96:1020–1025

    Article  Google Scholar 

  114. Inoue Y, Nemoto Y, Murata R, Tashiro T, Shakudo M, Kohno K, Matsuoka O, Mochizuki K (1998) CT and MR imaging of cerebral tuberous sclerosis. Brain Dev 20:209–221

    Article  CAS  PubMed  Google Scholar 

  115. Goodman M, Lamm SH, Engel A, Shepherd CW, Houser OW, Gomez MR (1997) Cortical tuber count: a biomarker indicating neurologic severity of tuberous sclerosis complex. J Child Neurol 12:85–90

    Article  CAS  PubMed  Google Scholar 

  116. Jansen FE, Vincken KL, Algra A, Anbeek P, Braams O, Nellist M, Zonnenberg BA, Jennekens-Schinkel A, van den Ouweland A, Halley D, van Huffelen AC, van Nieuwenhuizen O (2008) Cognitive impairment in tuberous sclerosis complex is a multifactorial condition. Neurology 70:916–923

    Article  CAS  PubMed  Google Scholar 

  117. Goh S, Butler W, Thiele EA (2004) Subependymal giant cell tumors in tuberous sclerosis complex. Neurology 63:1457–1461

    Article  PubMed  Google Scholar 

  118. Nishio S, Morioka T, Suzuki S, Kira R, Mihara F, Fukui M (2001) Subependymal giant cell astrocytoma: clinical and neuroimaging features of four cases. J Clin Neurosci 8:31–34

    Article  CAS  PubMed  Google Scholar 

  119. O’Callaghan FJ, Martyn CN, Renowden S, Noakes M, Presdee D, Osborne JP (2008) Subependymal nodules, giant cell astrocytomas and the tuberous sclerosis complex: a population-based study. Arch Dis Child 93:751–754

    Article  CAS  PubMed  Google Scholar 

  120. Torres OA, Roach ES, Delgado MR, Sparagana SP, Sheffield E, Swift D, Bruce D (1998) Early diagnosis of subependymal giant cell astrocytoma in patients with tuberous sclerosis. J Child Neurol 13:173–177

    Article  CAS  PubMed  Google Scholar 

  121. Griffiths PD, Bolton P, Verity C (1998) White matter abnormalities in tuberous sclerosis complex. Acta Radiol 39:482–486

    Article  CAS  PubMed  Google Scholar 

  122. Joinson C, O’Callaghan FJ, Osborne JP, Martyn C, Harris T, Bolton PF (2003) Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex. Psychol Med 33:335–344

    Article  CAS  PubMed  Google Scholar 

  123. Gupta A, de Bruyn G, Tousseyn S, Krishnan B, Lagae L, Agarwal N, Consortium TSCNHD (2020) Epilepsy and neurodevelopmental comorbidities in tuberous sclerosis complex: a natural history study. Pediatr Neurol 106:10–16

    Article  Google Scholar 

  124. de Groen AC, Bolton J, Bergin AM, Sahin M, Peters JM (2019) The evolution of subclinical seizures in children with tuberous sclerosis complex. J Child Neurol 34:770–777

    Article  PubMed  Google Scholar 

  125. Wu JY, Peters JM, Goyal M, Krueger D, Sahin M, Northrup H, Au KS, Cutter G, Bebin EM (2016) Clinical electroencephalographic biomarker for impending epilepsy in asymptomatic tuberous sclerosis complex infants. Pediatr neurol 54:29–34

    Article  PubMed  Google Scholar 

  126. Muzykewicz DA, Costello DJ, Halpern EF, Thiele EA (2009) Infantile spasms in tuberous sclerosis complex: prognostic utility of EEG. Epilepsia 50:290–296

    Article  PubMed  Google Scholar 

  127. Curatolo P, Nabbout R, Lagae L, Aronica E, Ferreira JC, Feucht M, Hertzberg C, Jansen AC, Jansen F, Kotulska K, Moavero R, O’Callaghan F, Papavasiliou A, Tzadok M, Jozwiak S (2018) Management of epilepsy associated with tuberous sclerosis complex: updated clinical recommendations. Eur J Paediatr Neurol 22:738–748

    Article  PubMed  Google Scholar 

  128. Kotulska K, Kwiatkowski DJ, Curatolo P, Weschke B, Riney K, Jansen F, Feucht M, Krsek P, Nabbout R, Jansen AC, Wojdan K, Sijko K, Glowacka-Walas J, Borkowska J, Sadowski K, Domanska-Pakiela D, Moavero R, Hertzberg C, Hulshof H, Scholl T, Benova B, Aronica E, de Ridder J, Lagae L, Jozwiak S, Investigators E (2021) Prevention of epilepsy in infants with tuberous sclerosis complex in the EPISTOP Trial. Ann neurol 89:304–314

    Article  CAS  PubMed  Google Scholar 

  129. Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA (2010) The natural history of epilepsy in tuberous sclerosis complex. Epilepsia 51:1236–1241

    Article  PubMed  Google Scholar 

  130. Fang Y, Li D, Wang M, Zhao X, Duan J, Gu Q, Li B, Zha J, Mei D, Bian G, Zhang M, Zhang H, Hu J, Yang L, Yu L, Li H, Liao J (2022) Ketogenic diet therapy for drug-resistant epilepsy and cognitive impairment in children with tuberous sclerosis complex. Front Neurol 13:863826

    Article  PubMed  PubMed Central  Google Scholar 

  131. Tong X, Wang X, Qin L, Zhou J, Guan Y, Teng P, Wang J, Yang Y, Li T, Luan G (2022) Vagus nerve stimulation for drug-resistant epilepsy induced by tuberous sclerosis complex. Epilepsy Behav 126:108431

    Article  PubMed  Google Scholar 

  132. Karenfort M, Kruse B, Freitag H, Pannek H, Tuxhorn I (2002) Epilepsy surgery outcome in children with focal epilepsy due to tuberous sclerosis complex. Neuropediatrics 33:255–261

    Article  CAS  PubMed  Google Scholar 

  133. Thiele EA, Bebin EM, Filloux F, Kwan P, Loftus R, Sahebkar F, Sparagana S, Wheless J (2022) Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: an open-label extension trial. Epilepsia 63:426–439

    Article  CAS  PubMed  Google Scholar 

  134. Franz DN, Lawson JA, Yapici Z, Brandt C, Kohrman MH, Wong M, Milh M, Wiemer-Kruel A, Voi M, Coello N, Cheung W, Grosch K, French JA (2018) Everolimus dosing recommendations for tuberous sclerosis complex-associated refractory seizures. Epilepsia 59:1188–1197

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Giordano F, Moscheo C, Lenge M, Biagiotti R, Mari F, Sardi I, Buccoliero AM, Mongardi L, Aronica E, Guerrini R, Genitori L (2020) Neurosurgical treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex: a series of 44 surgical procedures in 31 patients. Childs Nerv Syst 36:951–960

    Article  PubMed  Google Scholar 

  136. Teng JM, Cowen EW, Wataya-Kaneda M, Gosnell ES, Witman PM, Hebert AA, Mlynarczyk G, Soltani K, Darling TN (2014) Dermatologic and dental aspects of the 2012 International Tuberous Sclerosis Complex Consensus Statements. JAMA Dermatol 150:1095–1101

    Article  PubMed  Google Scholar 

  137. Ebrahimi-Fakhari D, Stires G, Hahn E, Krueger D, Franz DN (2021) Prenatal sirolimus treatment for rhabdomyomas in tuberous sclerosis. Pediatr Neurol 125:26–31

    Article  PubMed  Google Scholar 

  138. Maher ER, Yates JR, Harries R, Benjamin C, Harris R, Moore AT, Ferguson-Smith MA (1990) Clinical features and natural history of von Hippel-Lindau disease. Q J Med 77:1151–1163

    Article  CAS  PubMed  Google Scholar 

  139. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH (2003) von Hippel-Lindau disease. Lancet 361:2059–2067

    Article  CAS  PubMed  Google Scholar 

  140. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L et al (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317–1320

    Article  CAS  PubMed  Google Scholar 

  141. Kim WY, Kaelin WG (2004) Role of VHL gene mutation in human cancer. J Clin Oncol 22:4991–5004

    Article  CAS  PubMed  Google Scholar 

  142. Kaelin WG Jr (2002) Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2:673–682

    Article  CAS  PubMed  Google Scholar 

  143. Sufan RI, Jewett MA, Ohh M (2004) The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma. Am J Physiol Renal Physiol 287:F1-6

    Article  CAS  PubMed  Google Scholar 

  144. Barry RE, Krek W (2004) The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis. Trends Mol Med 10:466–472

    Article  CAS  PubMed  Google Scholar 

  145. Keith B, Johnson RS, Simon MC (2011) HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 12:9–22

    Article  PubMed  PubMed Central  Google Scholar 

  146. Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B, Simon MC, Nathanson KL (2008) HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14:435–446

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  147. Monzon FA, Alvarez K, Peterson L, Truong L, Amato RJ, Hernandez-McClain J, Tannir N, Parwani AV, Jonasch E (2011) Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis. Mod Pathol 24:1470–1479

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  148. de Paulsen N, Brychzy A, Fournier MC, Klausner RD, Gnarra JR, Pause A, Lee S (2001) Role of transforming growth factor-alpha in von Hippel-Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci USA 98:1387–1392

    PubMed  PubMed Central  Google Scholar 

  149. Zbar B, Kishida T, Chen F, Schmidt L, Maher ER, Richards FM, Crossey PA, Webster AR, Affara NA, Ferguson-Smith MA, Brauch H, Glavac D, Neumann HP, Tisherman S, Mulvihill JJ, Gross DJ, Shuin T, Whaley J, Seizinger B, Kley N, Olschwang S, Boisson C, Richard S, Lips CH, Lerman M et al (1996) Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 8:348–357

    Article  CAS  PubMed  Google Scholar 

  150. Wanebo JE, Lonser RR, Glenn GM, Oldfield EH (2003) The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg 98:82–94

    Article  PubMed  Google Scholar 

  151. Conway JE, Chou D, Clatterbuck RE, Brem H, Long DM, Rigamonti D (2001) Hemangioblastomas of the central nervous system in von Hippel-Lindau syndrome and sporadic disease. Neurosurgery 48:55–62; discussion 62–53

  152. Lonser RR, Weil RJ, Wanebo JE, DeVroom HL, Oldfield EH (2003) Surgical management of spinal cord hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg 98:106–116

    Article  PubMed  Google Scholar 

  153. Weil RJ, Lonser RR, DeVroom HL, Wanebo JE, Oldfield EH (2003) Surgical management of brainstem hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg 98:95–105

    Article  PubMed  Google Scholar 

  154. Eskridge JM, McAuliffe W, Harris B, Kim DK, Scott J, Winn HR (1996) Preoperative endovascular embolization of craniospinal hemangioblastomas. AJNR Am J Neuroradiol 17:525–531

    CAS  PubMed  PubMed Central  Google Scholar 

  155. Tampieri D, Leblanc R, TerBrugge K (1993) Preoperative embolization of brain and spinal hemangioblastomas. Neurosurgery 33:502–505; discussion 505

  156. Shimada K, Yamamoto Y, Miyamoto T, Sogabe S, Fujihara T, Nakajima K, Mizobuchi Y, Kanematsu Y, Takagi Y (2021) Efficacy of Intra-arterial Indocyanine green videoangiography in hemangioblastoma surgery: a case report. NMC Case Rep J 8:295–300

    Article  PubMed  PubMed Central  Google Scholar 

  157. Fukuda M, Takao T, Hiraishi T, Yoshimura J, Yajima N, Saito A, Fujii Y (2014) Clinical factors predicting outcomes after surgical resection for sporadic cerebellar hemangioblastomas. World Neurosurg 82:815–821

    Article  PubMed  Google Scholar 

  158. Kanno H, Yamamoto I, Nishikawa R, Matsutani M, Wakabayashi T, Yoshida J, Shitara N, Yamasaki I, Shuin T, Clinical VHLRGiJ (2009) Spinal cord hemangioblastomas in von Hippel-Lindau disease. Spinal Cord 47:447–452

    Article  CAS  PubMed  Google Scholar 

  159. Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R, Investigators MK (2021) Belzutifan for renal cell carcinoma in von Hippel-Lindau Disease. N Engl J Med 385:2036–2046

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  160. Jonasch E, McCutcheon IE, Gombos DS, Ahrar K, Perrier ND, Liu D, Robichaux CC, Villarreal MF, Weldon JA, Woodson AH, Pilie PG, Fuller GN, Waguespack SG, Matin SF (2018) Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial. Lancet Oncol 19:1351–1359

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  161. Kano H, Shuto T, Iwai Y, Sheehan J, Yamamoto M, McBride HL, Sato M, Serizawa T, Yomo S, Moriki A, Kohda Y, Young B, Suzuki S, Kenai H, Duma C, Kikuchi Y, Mathieu D, Akabane A, Nagano O, Kondziolka D, Lunsford LD (2015) Stereotactic radiosurgery for intracranial hemangioblastomas: a retrospective international outcome study. J Neurosurg 122:1469–1478

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Cairo University, 1 University Street, Giza Governorate, 12613, Egypt

    M. Elbeltagy

  2. Department of Neurosurgery, Children’s Cancer Hospital Egypt, Sekat Hadid Al Mahger, Zeinhom, El Sayeda Zeinab, Cairo Governorate, 4260102, Egypt

    M. Elbeltagy & M. Abbassy

  3. Department of Neurosurgery, Alexandria University, 22 El-Gaish Rd, Al Azaritah WA Ash Shatebi, Bab Sharqi, Alexandria Governorate, 5424041, Egypt

    M. Abbassy

Authors
  1. M. Elbeltagy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Abbassy
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

M.E and M.A wrote the manuscript, M.E revised it and supervised the manuscript.

Corresponding author

Correspondence to M. Elbeltagy.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Elbeltagy, M., Abbassy, M. Neurofibromatosis type1, type 2, tuberous sclerosis and Von Hippel-Lindau disease. Childs Nerv Syst 39, 2791–2806 (2023). https://doi.org/10.1007/s00381-023-06160-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00381-023-06160-3

Keywords

Search

Navigation